Red White & Bloom (CSE: RWB – IPO September 2019) CEO Brad Rogers recently sat down with cannabis best-selling author and Managing Director of Benzinga Cannabis Javier Hasse at the Benzinga Cannabis Capital Conference in Detroit, Michigan.
As RWB gears up for its highly anticipated IPO this September, Brad and Javier discuss various topics such as the current state of the industry, removing the cannabis stigma, cannabis vs alcohol, CBD’s massive potential and the human body’s endocannabinoid system.
Brad also touches on the company’s go public strategy in addition to the key differentiators that make RWB stand out as an attractive investment compared to its U.S. MSOs peers Curaleaf (CSE: CURA), Green Thumb (CSE: GTII) and Cresco Labs (CSE: CL). All three of these MSOs just received bullish reviews and price targets from one of Wall Street’s top cannabis analysts. RWB compares favourably to these companies and will likely catch the attention of Wall Street analysts soon after its IPO if it hasn’t already.
For additional information, you can watch Brad’s Benzinga video presentation in the video below. Brad covers additional topics including the RWB investment opportunity, revenue projections, market cap compared to Multi-State Operator (MSO) peers, the Michigan & Illinois market, their acquisition of the World’s Largest Indoor CBD/Hemp Facility, branding strategy and more.
Additional RWB Investment Highlights
- 9 figure revenues
- Raised $125 million privately
- Stacked management team with proven industry veterans
- Management team has created $3.5 billion in public company value on their previous deals
- No super-voting shares
Join our SMS/Text Message List by Texting the word potstocks to 866-219-8112
Move Over Curaleaf, There’s a New MSO in Town and it’s Set to Hit The Street This September
Get the full details here so you don’t miss out on the next potential 10 bagger.
Disclaimer: The Cannabis Investor owns a position in RWB.